Stock

NewAmsterdam Pharma Company N.V. NAMS

$30.74+0.61%

All stocks Create account to unlock

Overview

NAMS market data

Price History

NAMS price chart

Valuation & Profitability

no valuation data

No Valuation Data Yet

Alpha Vantage and Twelve Data both returned no valuation metrics for NAMS. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.

Company news

4 captured

NewAmsterdam Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Recommending Marketing Authorization For Ubeslo, Evlarco To Treat Primary Hypercholesterolemia · Jul 24, 2026, 12:01 PM

RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51 · Jun 30, 2026, 3:35 PM

NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions · Jun 3, 2026, 12:15 PM

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June · May 28, 2026, 12:15 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock